Gelsemium Sempervirens in Anticipatory Anxiety

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effectiveness of Gelsemium sempervirens 5CH et 15CH on anticipatory provoked anxiety, in healthy volunteers.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Grenoble
• Collaborator: BOIRON

Criteria

Inclusion Criteria:

• Man or woman,

• age between 18 et 40 ans,

• affiliated to a regime of social security or equivalent

Exclusion Criteria:

• Medical history of psychiatric disease relevant of psychoses,

• Medical history of hospitalisation in psychiatric environment,

• psychotropic substance of the class of antidepressants, antipsychotics and normothymics), in the year before inclusion,

• Taking, even punctual of psychotropics substances of the class of benzodiazepines and related, in the month before inclusion,

• Taking, even punctual of psychotropics substances of the class of anxiolytics non benzodiazepines, in the month before inclusion: meprobamate, hydroxyzine, buspirone, captodiamine, pregabalin, etifoxine,

• Taking, even punctual of substances of the class of the sedatives divers, in the month before inclusion: phytotherapy, homeopathy, sedatives with brome, mineral elements,

• Taking, even punctual of substances of the class of antihistamine with hypnotic aim, in the month before inclusion,

• Taking, even punctual of propanolol in the month before inclusion

• Known Addiction,

• Handicap incompatible with the Stress Test : blindness, partially sighted, daltonism, dementia, language troubles,

• Pregnancy, parturient and nursing woman,

• Person private of freedom by judicial or administrative decision, person under measure of legal protection,

• allergy to one of the constituents